Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul 6;14(14):3294.
doi: 10.3390/cancers14143294.

Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer

Qinying Sun  1 , Xiangzhen Wei  2 , Zhonglin Wang  2 , Yan Zhu  2 , Weiying Zhao  2 , Yuchao Dong  1
Affiliations
Review

Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer

Qinying Sun et al. Cancers (Basel). .

Abstract

Immune checkpoint inhibitors have emerged as the treatment landscape of advanced non-small cell lung cancer (NSCLC) in recent years. However, approximately 80% of NSCLC patients do not benefit from ICIs due to primary resistance (no initial response) or acquired resistance (tumor relapse after an initial response). In this review, we highlight the mechanisms of primary and secondary resistance. Furthermore, we provide a future direction of the potential predictive biomarkers and the tumor microenvironmental landscape and suggest treatment strategies to overcome these mechanisms.

Keywords: immune check inhibitors; non-small cell lung cancer; primary and acquired resistance.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Primary and acquired mechanisms against ICIs in NSCLC.
See this image and copyright information in PMC

References

    1. Abedi S., Janbabaei G., Afshari M., Moosazadeh M., Rashidi Alashti M., Hedayatizadeh-Omran A., Alizadeh-Navaei R., Abedini E. Estimating the Survival of Patients with Lung Cancer: What Is the Best Statistical Model? J. Prev. Med. Public Health. 2019;52:140–144. doi: 10.3961/jpmph.17.090. - DOI - PMC - PubMed
    1. Wong S.K., Horn L. How I Treat Non-Small Cell Lung Cancer Refractory to Immunotherapy. Cancer J. 2020;26:496–501. doi: 10.1097/PPO.0000000000000482. - DOI - PubMed
    1. Garon E.B., Hellmann M.D., Rizvi N.A., Carcereny E., Leighl N.B., Ahn M.J., Eder J.P., Balmanoukian A.S., Aggarwal C., Horn L., et al. Five-Year Overall Survival for Patients with Advanced NonSmall-Cell Lung Cancer Treated with Pembrolizumab: Results from the Phase I KEYNOTE-001 Study. J. Clin. Oncol. 2019;37:2518–2527. doi: 10.1200/JCO.19.00934. - DOI - PMC - PubMed
    1. Gettinger S., Horn L., Jackman D., Spigel D., Antonia S., Hellmann M., Powderly J., Heist R., Sequist L.V., Smith D.C., et al. Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results from the CA209-003 Study. J. Clin. Oncol. 2018;36:1675–1684. doi: 10.1200/JCO.2017.77.0412. - DOI - PubMed
    1. Koustas E., Sarantis P., Papavassiliou A.G., Karamouzis M.V. The Resistance Mechanisms of Checkpoint Inhibitors in Solid Tumors. Biomolecules. 2020;10:666. doi: 10.3390/biom10050666. - DOI - PMC - PubMed

LinkOut - more resources